Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

481.67 +0.60 (+0.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M... 
Via Benzinga
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. 
Via Investor's Business Daily
Expert Ratings For Alnylam Pharmaceuticals
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed... 
Via Benzinga
10 Biggest Price Target Changes For Monday
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A... 
Via Benzinga
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE: 
Via Benzinga
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan
Novo Nordisk is buying an RNA interference company. 
Via Investor's Business Daily
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ra... 
Via Benzinga
Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript
ALNY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Why Alnylam Pharmaceuticals Stock Is Tanking This Week
The company missed analysts' Q3 revenue expectations and announced the departure of its CEO. 
Via The Motley Fool
Why Alnylam Pharmaceuticals Is Crashing Today
The company's earnings fell short of expectations and its CEO is leaving. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 21.62% to $2.25 during Thursday's regular session. Trading volume for Kiromic BioPharma's stock is... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug... 
Via Benzinga
Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit
Alnylam fell on a disappointing quarter and plans for CEO John Maraganore to exit. 
Via Investor's Business Daily
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Planned CEO Leadership Transition
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
3 Growth Stocks Near 52-Week Highs to Buy Anyway
These top performers have what it takes to keep providing outsized gains for patient investors. 
Via The Motley Fool
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ: 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.